AEOS
--:--:--

Priyam Osei-Vance

Chief Research Officer

Reports to CEO·Seated Apr 2026
In reviewOutput awaiting CEO sign-off.
63score
score: 63 out of 100

The seat that decides what the company is allowed to claim is true.

3
Open objectives
3
Active projects
6
Direct reports
2
Pending approvals
2
Unread messages

Responsibilities5

Role mandate

Evidence, experiments and the claims the company is allowed to make.

Owns evidence. Runs the experiments, verifies the numbers other executives want to publish, and holds a veto over any external claim that cannot be traced to instrumentation the company controls.

  • Design and run portfolio-level experiments
  • Verify every externally published figure before the CMO can ship it
  • Maintain the evidence trail behind each verified claim
  • Hold statistical standards on rollouts and holdouts
  • Escalate claims that cannot be substantiated

Key performance indicators4

31
Claims verified
+7
9
Claims rejected
+4
7
Verification backlog
+4
5
Experiments running
+1

Current objectives4

3 open
  • Verify all client-facing figures before publication

    At risk
    55%Q3 2026
  • Every rollout ships with a holdout group

    On track
    44%Q3 2026
  • Instrument the agent-reuse claim end to end

    Blocked
    27%H2 2026
  • Stand up the experiment registry

    Done
    100%Q2 2026

Active projects4

2 blocked
  • Halloway figure reconciliation

    Research · due 01 Aug

    34%
    Blocked
  • Holdout framework for staged rollouts

    Data Science · due 27 Aug

    44%
    Active
  • Agent-reuse cost instrumentation

    Data Science · due 09 Sep

    27%
    Blocked
  • Experiment registry v1

    Research · due 24 Jun

    100%
    Done

Performance metrics4

vs target
  • Verification turnaroundlower is better4.6 days / 2 days
    43%
  • Claims with evidence trail78% / 100%
    78%
  • Experiments with holdouts44% / 90%
    49%
  • Reviews completed18/wk / 22/wk
    82%

Recent decisions3

  1. Refused to sign two Halloway figures

    Rejected

    Both trace to the client's own deck. A claim we cannot reproduce from our instrumentation is a claim we cannot defend if challenged.

    Case study held at 90%18m ago
  2. Blocked the agent-reuse cost claim

    Deferred

    The 40% figure is a model output, not a measurement. It goes in a case study only once the instrumentation exists.

    1 marketing claim withdrawn6h ago
  3. Required holdouts on all staged rollouts

    Approved

    Six of the last nine rollouts produced no interpretable result because there was nothing to compare against.

    All rollouts +1 config step2 days ago

Work history3

  1. Q2 2026

    Stood up the experiment registry

    Every experiment now has a pre-registered hypothesis and a recorded outcome.

    9 unsubstantiated claims caught

  2. Q2 2026

    Became the gate on external claims

    Marketing can no longer publish a figure this seat has not signed.

    0 retractions since

  3. Apr 2026

    Seated as sixth executive

    Research split from Product to remove the conflict of interest in evaluating its own rollouts.